These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 16893429

  • 1. Metabolic approach to heart failure - evidence that trimetazidine improves symptoms, left ventricular function and possibly prognosis.
    Jackson G.
    Int J Clin Pract; 2006 Aug; 60(8):891-2. PubMed ID: 16893429
    [No Abstract] [Full Text] [Related]

  • 2. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure.
    Fragasso G, Perseghin G, De Cobelli F, Esposito A, Palloshi A, Lattuada G, Scifo P, Calori G, Del Maschio A, Margonato A.
    Eur Heart J; 2006 Apr; 27(8):942-8. PubMed ID: 16510466
    [Abstract] [Full Text] [Related]

  • 3. Trimetazidine: the future of cardiac function?
    Di Napoli P, Taccardi AA.
    Future Cardiol; 2009 Sep; 5(5):421-4. PubMed ID: 19715405
    [No Abstract] [Full Text] [Related]

  • 4. [Effects of trimetazidine on serum oxygen free radicals in congestive heart failure].
    Ma QL, Xie Y, Zhang SD.
    Hunan Yi Ke Da Xue Xue Bao; 2002 Dec 28; 27(6):527-9. PubMed ID: 12658930
    [Abstract] [Full Text] [Related]

  • 5. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure.
    Gao D, Ning N, Niu X, Hao G, Meng Z.
    Heart; 2011 Feb 28; 97(4):278-86. PubMed ID: 21134903
    [Abstract] [Full Text] [Related]

  • 6. [Effect of atenolol and trimetazidine on dispersion of cardiac rhythm in patients with moderately expressed postinfarction left ventricular dysfunction].
    Kaliuzhin VV, Tepliakov AT, Kamaev DIu, Solovtsov MA.
    Ter Arkh; 2002 Feb 28; 74(8):42-4. PubMed ID: 12360593
    [Abstract] [Full Text] [Related]

  • 7. Role of trimetazidine in management of ischemic cardiomyopathy.
    Bertomeu-Gonzalez V, Bouzas-Mosquera A, Kaski JC.
    Am J Cardiol; 2006 Sep 04; 98(5A):19J-24J. PubMed ID: 16931202
    [Abstract] [Full Text] [Related]

  • 8. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure.
    Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, Calori G, Alfieri O, Margonato A.
    J Am Coll Cardiol; 2006 Sep 05; 48(5):992-8. PubMed ID: 16949492
    [Abstract] [Full Text] [Related]

  • 9. Metabolic therapy for heart failure.
    Essop MF, Opie LH.
    Eur Heart J; 2004 Oct 05; 25(20):1765-8. PubMed ID: 15474689
    [No Abstract] [Full Text] [Related]

  • 10. Trimetazidine improves myocardial perfusion and left ventricular function in ischemic left ventricular dysfunction.
    Feola M, Biggi A, Francini A, Leonardi G, Ribichini F, Ferrero V, Uslenghi E.
    Clin Nucl Med; 2004 Feb 05; 29(2):117-8. PubMed ID: 14734913
    [No Abstract] [Full Text] [Related]

  • 11. Metabolic modulation as a target for heart failure treatment: current perspective.
    Chenniapan S, Manchanda SC.
    Indian Heart J; 2007 Feb 05; 59(4):370-4. PubMed ID: 19126947
    [No Abstract] [Full Text] [Related]

  • 12. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial.
    Di Napoli P, Di Giovanni P, Gaeta MA, Taccardi AA, Barsotti A.
    J Cardiovasc Pharmacol; 2007 Nov 05; 50(5):585-9. PubMed ID: 18030070
    [Abstract] [Full Text] [Related]

  • 13. [Clinical and diagnostic indications for the use of nitrates in dynamic heart defects (decompensation, left ventricular dysfunction without decompensation, etc].
    Branzi A.
    G Ital Cardiol; 1996 Sep 05; 26(9):1079-84. PubMed ID: 9036049
    [No Abstract] [Full Text] [Related]

  • 14. Metabolic modulation in heart failure: high time for a definitive clinical trial.
    Ashrafian H, Neubauer S.
    Heart; 2011 Feb 05; 97(4):267-8. PubMed ID: 21258118
    [No Abstract] [Full Text] [Related]

  • 15. Trimetazidine improves right ventricular function by increasing miR-21 expression.
    Liu F, Yin L, Zhang L, Liu W, Liu J, Wang Y, Yu B.
    Int J Mol Med; 2012 Oct 05; 30(4):849-55. PubMed ID: 22842854
    [Abstract] [Full Text] [Related]

  • 16. [Ischemic heart disease and left ventricular dysfunction: the role of trimetazidine].
    Belardinelli R.
    Ital Heart J; 2004 Mar 05; 5 Suppl 2():23S-28S. PubMed ID: 15074774
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The metabolic approach in patients with heart failure: effects on left ventricle remodeling.
    Tang WH.
    Curr Pharm Des; 2009 Mar 05; 15(8):850-6. PubMed ID: 19275649
    [Abstract] [Full Text] [Related]

  • 19. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease.
    Lu C, Dabrowski P, Fragasso G, Chierchia SL.
    Am J Cardiol; 1998 Oct 01; 82(7):898-901. PubMed ID: 9781975
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.